LOGIN
ID
PW
MemberShip
2025-10-16 05:17
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Risk-Sharing Agreements in the EU: A Systematic Review
Risk-Sharing Agreements in the EU: A Systematic Review
of Major Trends
Input Time : 2019-11-15
[Download file]
go back
OPINION
[Op-Ed] Patients, no time left for 'new drug comb therapies'
Special Contribution |
Eo, Yun-Ho
[Desk¡¯s View] Lift botulinum toxin¡¯s core tech designation
Desk's view |
Lee, Seok-Jun
[Reporter's View] 'National Core Tech' status for Botox
Reporter's view |
Hwang, byoung woo
INTERVIEW
"New landscape in DLBCL trt¡¦Columvi¡¤Polivy's bigger role"
Professor Gareth Gregory of Monash University in Australia
"Gilead-Kite will lead the trt landscape for DLBCL in KOR"
Diego Santoro, Head of the International Region for Kite Pharma
Dong-A ST launches Sterlara biosimilar Imuldosa in the US
V-olet challenges to become a blockbuster fat-destroying inj
Kim Seul-ki, PM of Daewoong Pharmaceutical's Nabota Business Team
'Viatris will lead market with innovation and leadership'
Bill Schuster, Representative Director & Country Manager of Viatris Korea
Data
Roche 2018 Annualreport
Roche 2018 Annualreport
NOVARTIS 2018 Annualreport
NOVARTIS 2018 Annualreport
2018 Multinational Pharma Sales
2018 Multinational Pharma Sales
MOST READ
1
Hugel appoints Carrie Strom as global CEO
2
Ozempic nears reimb approval¡¦next is Mounjaro
3
New Divisions for Essential & Public Healthcare proposed
4
Demands for expanded reimbursement for NMOSD
5
¡®Leclaza combo extends survival without chemotherapy¡¯
6
Gov't to unveil New drugs¡¤Generic Drug Pricing System Rev.
7
Only Ozempic undergoes DREC review for reimb, not Mounjaro
8
GSK¡¯s myelofibrosis drug Omjjara faces reimb hurdles
9
Entresto patent dispute near its end, yet 0 generic approval
10
No companies apply for domestic API pricing premium